ReviewJournal of clinical hypertension (Greenwich, Conn.)2006
Targeting nitric oxide with drug therapy.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril.European journal of clinical pharmacology · 2013Trial
- Nebivolol efficacy and safety in patients with stage I-II hypertension.Clinical cardiology · 2010Trial
- Role of S1P- and Rho-kinase signalling in age-related myogenic tone deficiency in murine resistance arteries.Experimental physiology · 2026Article
- GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer outcomes.Scientific reports · 2025Article
- Nebivolol: an effective option against long-lasting dyspnoea following COVID-19 pneumonia - a pivotal double-blind, cross-over controlled study.Multidisciplinary respiratory medicine · 2022Article
- Angelica polysaccharide attenuates LPS-induced inflammation response of primary dairy cow claw dermal cells via NF-κB and MAPK signaling pathways.BMC veterinary research · 2021Article
- Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.World journal of urology · 2020Review
- The Flow Limiting Operator: A New Approach to Environmental Control in Flow Bioreactors.RSC advances · 2020Article
- Angelicae Gigantis Radix Regulates LPS-Induced Neuroinflammation in BV2 Microglia by Inhibiting NF-κB and MAPK Activity and Inducing Nrf-2 Activity.Molecules (Basel, Switzerland) · 2019Article
- Article
- Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.Gene · 2016 · on this mapReview
- Reconstitution of coronary vasculature by an active fraction of Geum japonicum in ischemic hearts.Scientific reports · 2014Article
- A series of N-(2-phenylethyl)nitroaniline derivatives as precursors for slow and sustained nitric oxide release agents.Acta crystallographica. Section C, Crystal structure communications · 2013Article
- Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variants.British journal of clinical pharmacology · 2012Article
- Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?Arteriosclerosis, thrombosis, and vascular biology · 2012Review
- β-blockade: benefits beyond blood pressure reduction?Journal of clinical hypertension (Greenwich, Conn.) · 2012Review
- Advances in pharmacologic modulation of nitric oxide in hypertension.Current cardiology reports · 2010Review
- Mechanistic studies on the reaction between R2N-NONOates and aquacobalamin: evidence for direct transfer of a nitroxyl group from R2N-NONOates to cobalt(III) centers.Angewandte Chemie (International ed. in English) · 2009Article
- Pharmacogenetic Implications of eNOS Polymorphisms (In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing knowledge of the role of nitric oxide (NO) in physiology and disease has stimulated efforts to target the NO pathway pharmacologically. These therapeutic strategies include NO donors that directly or indirectly release NO and agents that increase NO bioactivity. Traditional organic nitrates such as nitroglycerin, which indirectly release NO, were believed to have limited long-term efficacy and tolerability, chiefly because of nitrate tolerance. Recent studies, however, suggest more effective ways of using these agents and new applications for them. Nicorandil, a hybrid organic nitrate that also activates potassium channels, has demonstrated significant benefits in acute coronary syndromes. Other nitrates are being investigated for use in neurodegenerative diseases. Direct NO donors include NO gas, which is useful in respiratory disorders, and the more recent classes of diazeniumdiolates, sydnonimines, and S-nitrosothiols. Preliminary data suggest that these agents may be effective as antiatherosclerotic agents as well as in other disease states. In addition, hybrid agents that consist of an NO donor coupled with a parent anti-inflammatory drug, including nonsteroidal anti-inflammatory drugs, have demonstrated enhanced efficacy and tolerability compared with the anti-inflammatory parent drug alone in diverse experimental models. Established drugs that enhance NO bioactivity include antihypertensive agents, particularly angiotensin-converting enzyme inhibitors, calcium channel blockers, and newer vasodilating beta-blockers. In addition, 3-methylglutaryl coenzyme A reductase inhibitors (statins) promote NO bioactivity, both through and independent of lipid lowering. The NO-promoting actions of these established drugs provide some insight into their known benefits and suggest possible therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.